

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 5





Figure 6






Figure 7:


A



ER alpha signature
 estropipate (9200 nM)
 equilin (15000 nM)
 estradiol (10 nM)
 raloxifene (7800 nM)
 naringenin (14600 nM)
 fulvestrant (10 nM)
 estradiol (100 nM)
 levonorgestrel (12800 nM)
 lorglumide (8400 nM)
 genistein (10000 nM)



B



ER alpha signature
 GDS3315: ChX vs. estradiol and ChX
 GDS3283: control vs. estradiol
 GDS3217: control vs. estradiol
 GDS3315: control vs. estradiol and ChX
 GDS1094: 17beta-estradiol vs. control
 GDS1094: 17beta-estradiol vs. 4OH-tamoxifen
 GDS3315: control vs. estradiol
 GDS2367: tamoxifen vs. vehicle
 GDS3285: estradiol 0 h vs. 3 h
 GDS2770: 17beta-estradiol vs. control










Figure S1




Supp Fig S2



Supp Fig S3



Supp Fig S4



Supp Fig S5

